Pharmacology · Antifungal Agents

Allylamines, Flucytosine, and Griseofulvin

Three distinct mechanisms, three narrow clinical niches

Terbinafine targets squalene epoxidase — earlier in the ergosterol biosynthesis pathway than azoles — producing both ergosterol depletion and accumulation of toxic squalene; the dual mechanism makes it fungicidal against dermatophytes rather than merely fungistatic.
Flucytosine is a prodrug that fungal cells convert to 5-fluorouracil — blocking DNA synthesis and disrupting RNA processing; mammalian cells lack the deaminase enzyme required for this conversion, explaining its selective fungal toxicity at therapeutic concentrations.
Flucytosine must never be used as monotherapy — resistance emerges within days through loss of cytosine permease or deaminase activity; it is only effective and only indicated in combination with amphotericin B, where membrane permeabilization by amphotericin B enhances flucytosine uptake.
Griseofulvin disrupts the fungal mitotic spindle by binding β-tubulin — it is fungistatic and active only against dermatophytes; it remains preferred for tinea capitis caused by Microsporum canis, where terbinafine is less effective due to species-specific differences in drug susceptibility.
Terbinafine is a CYP2D6 inhibitor — relevant for co-prescribed tricyclic antidepressants, beta-blockers, and antiarrhythmics metabolized by CYP2D6; griseofulvin is a CYP3A4 inducer and reduces efficacy of oral contraceptives, warfarin, and cyclosporine.

Abbreviations: 5-FU = 5-fluorouracil · CYP2D6 = cytochrome P450 2D6 · CYP3A4 = cytochrome P450 3A4 · TDM = therapeutic drug monitoring · CBC = complete blood count · GI = gastrointestinal · DNA = deoxyribonucleic acid · RNA = ribonucleic acid

Mechanism and Spectrum

Allylamines

Terbinafine

Mechanism

Inhibits squalene epoxidase — blocks conversion of squalene → lanosterol (earlier than azoles in ergosterol pathway)
Dual effect: ergosterol depletion + squalene accumulation → membrane disruption
Fungicidal against dermatophytes (not fungistatic)

Clinical Niche

Dermatophyte onychomycosis — drug of choice; 6 weeks (fingernail), 12 weeks (toenail)
Tinea capitis from Trichophyton tonsurans — preferred over griseofulvin
No activity against Candida, Aspergillus, or non-dermatophyte molds

Flucytosine (5-FC)

5-Fluorocytosine

Mechanism

Transported into fungal cells via cytosine permease → converted by cytosine deaminase to 5-FU
5-FU → fluorinated nucleotides → inhibits thymidylate synthase (DNA synthesis) + disrupts RNA function
Mammalian cells lack cytosine deaminase → selective fungal toxicity

Clinical Niche

Cryptococcal meningitis induction: amphotericin B + flucytosine × 2 weeks (IDSA) or × 1 week (WHO 2022 short-course)
Candida infections (combination only, rarely used)
NEVER as monotherapy — resistance emerges in days

Griseofulvin

Mechanism

Binds β-tubulin → inhibits fungal microtubule polymerization → arrests mitosis
Accumulates in keratin-rich tissue (nail, skin, hair) → localizes to site of infection
Fungistatic — relies on host defenses to clear infection

Clinical Niche

Tinea capitis in children, especially Microsporum canis — where terbinafine has reduced efficacy
Dermatophyte skin infections when other agents fail
Dermatophytes only; no activity against Candida, Aspergillus, or yeasts

Clinical Properties Comparison

Feature	Terbinafine	Flucytosine	Griseofulvin
Route	Oral (tablet) or topical (cream); good tissue penetration	Oral; IV available but oral preferred when GI tract functional	Oral only; take with fatty meal — fat enhances absorption
Key Toxicity	Hepatotoxicity (rare, idiosyncratic); taste disturbance (ageusia); GI upset	Myelosuppression (leukopenia, thrombocytopenia) — concentration-dependent; GI effects	Headache; GI effects; photosensitivity; disulfiram-like reaction with alcohol; teratogenic
Drug Interactions	CYP2D6 inhibition — ↑ tricyclic antidepressants, beta-blockers, antiarrhythmics, codeine; check full medication list	Accumulates in renal impairment (primarily renal elimination) — dose-adjust; concurrent amphotericin B worsens renal function → flucytosine accumulates → toxicity	CYP3A4 inducer — ↓ oral contraceptives (use barrier method), warfarin, cyclosporine; alcohol → disulfiram-like reaction
Monitoring	LFTs at baseline for long courses; symptoms of hepatotoxicity	TDM required — peak 50–100 mg/L (2-hour post-dose); CBC twice weekly; serum creatinine frequently	No routine monitoring; counsel on alcohol avoidance and photosensitivity
Special Caution	Avoid in severe hepatic impairment; CYP2D6 interactions in polypharmacy patients	Monotherapy absolutely contraindicated; flucytosine alone → resistance within days; check renal function before each dose adjustment	Teratogenic — contraindicated in pregnancy and for 1 month before conception; avoid in porphyria; lupus exacerbation risk

Flucytosine + Amphotericin B Synergy

Why the Combination Is Synergistic

Membrane Permeabilization Enhances 5-FC Uptake

Amphotericin B disrupts fungal membrane → increases permeability
Enhanced flucytosine entry via cytosine permease and non-specific leak across disrupted membrane
Lower concentrations of both drugs needed for fungicidal effect → reduced toxicity compared to full doses of either alone
Clinical evidence: ACTG 5164 and IDSA guidelines confirm AmB + 5-FC superior to AmB monotherapy for cryptococcal meningitis
WHO 2022: 1-week induction (L-AmB + 5-FC) shown non-inferior to 2-week induction in African trials — reduces 5-FC-related myelotoxicity

Monotherapy Resistance — Absolute Contraindication

Flucytosine Resistance Emerges Within Days

Resistance mechanisms: loss of cytosine permease (transport failure) or cytosine deaminase (conversion failure)
De novo resistance or outgrowth of resistant subpopulations occurs within days of monotherapy exposure
Combination with amphotericin B slows resistance emergence and restores fungicidal activity
Flucytosine is not available in all countries — when unavailable for cryptococcal meningitis, proceed with AmB alone rather than delay; do not substitute fluconazole for flucytosine in induction
Pre-treatment susceptibility testing recommended if prior 5-FC exposure or azole-treated disease

Clinical Niche Summary — When to Use Each Agent

Terbinafine is the drug of choice for dermatophyte onychomycosis and for tinea capitis caused by Trichophyton tonsurans — the most common cause of tinea capitis in the US. It is fungicidal against dermatophytes and achieves excellent nail and hair concentrations. When the causative species is Microsporum canis — common in children in Europe and Latin America — griseofulvin has superior cure rates because terbinafine has reduced activity against this species.

Flucytosine has exactly one current indication: cryptococcal meningitis induction in combination with amphotericin B (liposomal preferred). The WHO 2022 guidelines support a 1-week induction regimen (liposomal AmB + flucytosine) as non-inferior to 2 weeks, with fewer hematologic adverse events. Outside of cryptococcal disease, flucytosine has no established role in contemporary antifungal practice — polyenes, azoles, and echinocandins are more effective and better tolerated for all other indications.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter 48: Antifungal Agents	McGraw-Hill, 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 57: Antifungal Agents	McGraw-Hill, 2023
Ryder NS	The mechanism of action of terbinafine	Clin Exp Dermatol. 1989;14(2):98–100
Balfour JA, Faulds D	Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses	Drugs. 1992;43(2):259–284
Gupta AK, Chow M, Daniel CR, et al.	Treatments of tinea pedis	Dermatol Clin. 2003;21(3):431–462
Vermes A, Guchelaar HJ, Dankert J	Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions	J Antimicrob Chemother. 2000;46(2):171–179
Andes D, Pascual A, Marchetti O	Antifungal therapeutic drug monitoring: established and emerging indications	Antimicrob Agents Chemother. 2009;53(1):24–34
Molloy SF, Kanyama C, Heyderman RS, et al.	Antifungal combinations for treatment of cryptococcal meningitis in Africa	N Engl J Med. 2018;378(11):1004–1017
World Health Organization	Guidelines for Diagnosing, Preventing and Managing Cryptococcal Disease Among Adults, Adolescents and Children Living with HIV	Geneva: WHO; 2022
Gupta AK, Cooper EA	Update in antifungal therapy of dermatophytosis	Mycopathologia. 2008;166(5–6):353–367
Elewski BE, Caceres HW, DeLeon L, et al.	Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials	J Am Acad Dermatol. 2008;59(1):41–54
Perfect JR, Dismukes WE, Dromer F, et al.	Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America	Clin Infect Dis. 2010;50(3):291–322